Saturday November 2

2019 9:00 am - 2:30 pm

UNIVERSITY OF ILLINOIS

AT CHICAGO COLLEGE OF PHARMACY

LIVE PROGRAM UIC College of Pharmacy

(Chicago) 833 S. Wood Street, Room 134-1

Chicago, Illinois 60612

LIVE BROADCAST UIC College of Pharmacy

(Rockford) 1601 Parkview Ave., Room E230

Rockford, Illinois 61107

A KNOWLEDGE-BASED SYMPOSIUM

A conference for pharmacists and other health care

professionals who care for patients

with cancer.

Please visit our website at: https://oncologysymposium.uic.edu/

LOCATION LIVE PROGRAM UIC College of Pharmacy (Chicago) 833 S. Wood Street, Room 134-1 Chicago, Illinois 60612

LIVE BROADCAST UIC College of Pharmacy (Rockford) 1601 Parkview Ave., Room E230 Rockford, Illinois 61107

TARGET AUDIENCE A conference for pharmacists and other health care professionals who care for patients with cancer.

PROGRAM DESCRIPTION New developments in pharmacotherapy and a better understanding of cancer origins continue to revolutionize the treatment of patients with cancer and challenge the clinical pharmacist to stay abreast of emerging therapies with novel toxicities. This conference will examine approaches to the treatment of hematologic malignancies and provide an overview of new drug therapies. Highlighted topics will include a review of the improvements in the assessment and management of Graft versus Host Disease (GVHD), updates in Chronic Lymphocytic Leukemia (CLL), updates in Hepatocellular Carcinoma (HCC), and new drug updates in Oncology. In addition, the symposium will include a session on Assessment and Management of Cancer Pain in the Setting of the Opioid Epidemic.

DISCLOSURES Speaker Disclosures: Dr. Radhakrishnan is a consultant at AstraZeneca and is on the speaker’s bureau/advisory board of Taiho Oncology, Inc., Kyowa Kinn, Exelixis, Inc. Dr. Wojenski received financial/ material support from Abbvie.

REGISTRATION DEADLINE Friday, October 25, 2019

QUESTIONS? Call toll-free at: (866) PHARMCE (742-7623).

CHAIR Sandra Cuellar, PharmD, BCOP Director, Specialty Residency in Oncology Clinical Assistant Professor Clinical Pharmacist, Oncology University of Illinois at Chicago College of Pharmacy

SPEAKERS Amanda N. Seddon, PharmD, BCPS, BCOP Director, PGY2 Oncology Pharmacy Residency Program Clinical Pharmacy Specialist, Hematology/Oncology/Cellular Therapy Rush University Medical Center Assistant Professor of Pharmacy Practice Midwestern University, Chicago College of Pharmacy

Daniel J. Wojenski, PharmD, BCPS, BCOP Hematology/Oncology Practice Coordinator PGY2 Hematology/Oncology Pharmacy Residency Coordinator PGY1 Pharmacy Practice Residency Coordinator Hematology/Stem Cell Transplant Clinical Pharmacist Northwestern Memorial Hospital

Latha Radhakrishnan, PharmD, BCPS, BCOP Clinical Pharmacist/Clinical Assistant Professor University of Illinois at Chicago College of Pharmacy Iman Suliman, PharmD Clinical Pharmacy Specialist, Palliative Care Dana-Farber Cancer Institute

Jamie Kalangara Thomas, PharmD PGY-2 Oncology Pharmacy Resident University of Illinois Hospital & Health Science

CE Advisory Committee Disclosures: The reviewers who contributed to this activity have no relevant conflict of interest to disclose in relation to this activity. All other speakers, members of the CE advisory committee and planning committee who contributed to this activity have no relevant conflicts of interest to disclose.

ACCREDITATION The University of Illinois at Chicago College of Pharmacy is

® accredited by the Accreditation Council for Pharmacy Education

(ACPE) as a provider of continuing pharmacy education. Pharmacists may earn up to a total of 3.75 contact hours (0.375 CEUs), as each session is accredited for 0.75 contact hours. Attendance at the entire knowledge-based activity, completion of the evaluation form, and submission of NABP eProfile ID and MMDD are prerequisites for receiving continuing pharmacy education credit(s) at each session. All ACPE credit awarded to participants must be uploaded to CPE Monitor™ within 30 days of the activity date, so pharmacists are required to provide their e-Profile ID and date of birth (MMDD) at the time of the activity. Please contact pharmce@uic.edu if you do not see activity information listed within 30 days. For more information and to set up your e-Profile visit: www.MyCPEmonitor.net.

This symposium has been assigned the following ACPE Universal Activity Number (UAN)s and contact hours:

• No JAKing around.

Improvements in the assessment and management of Graft versus Host Disease (GVHD) UAN# 0016-0000-19-058-L01-P 0.75 contact hour

• Updates in Chronic Lymphocytic Leukemia UAN# 0016-0000-19-059-L01-P 0.75 contact hour

• Updates in the Management of Hepatocellular Carcinoma UAN# 0016-0000-19-063-L01-P 0.75 contact hour

• Assessment and Management of Cancer Pain in the Setting of the Opioid Epidemic UAN# 0016-0000-19-064-L01-P 0.75 contact hour

• New Drug Updates in Oncology UAN# 0016-0000-19-060-L01-P 0.75 contact hour

AGENDA

8:00 a.m. – 9:00 a.m. Registration, Exhibits and Continental Breakfast

9:00 a.m. – 9:15 a.m. Welcome Sandra Cuellar, PharmD, BCOP

9:15 a.m. – 10:00 a.m. LEARNING OBJECTIVES:

No JAKing around. Improvements in the assessment and management of Graft versus Host Disease (GVHD) Amanda N. Seddon, PharmD, BCPS, BCOP • Describe the pathophysiology of graft-versus-host

disease • Identify stage and grade of acute or chronic GVHD • Select treatment options for acute and chronic GVHD

for a given patient scenario

10:00 a.m. – 10:45 a.m. LEARNING OBJECTIVES:

Updates in Chronic Lymphocytic Leukemia Daniel J. Wojenski, PharmD, BCPS, BCOP • Identify prognostic factors in Chronic Lymphocytic Leukemia

(CLL) and explain how they impact treatment decisions • Review the pharmacology of targeted therapies in CLL • Select a management care plan for front line therapy based

on patient specific factors • Discuss the current literature in relapsed and refractory CLL

and select an appropriate treatment regimen based on the patient’s prior lines of therapy

10:45 a.m. – 11:00 a.m. Break

11:00 a.m. – 11:45 a.m. LEARNING OBJECTIVES:

Updates in the Management of Hepatocellular Carcinoma Latha Radhakrishnan, PharmD, BCPS, BCOP • Review recently approved treatment options in the 1st and

2nd line setting in patients with advanced hepatocellular carcinoma (HCC)

• Determine treatment options based on patient specific factors • Recognize treatment-related toxicities and the associated

management strategies

11:45 a.m. – 1:00 p.m. Luncheon, Exhibits and Networking

1:00 p.m. – 1:45 p.m. LEARNING OBJECTIVES:

Assessment and Management of Cancer Pain in the Setting of the Opioid Epidemic Iman Suliman, PharmD • Identify the justification for incorporating opioid risk

assessment strategies into the management of oncology patients

• Review how to apply risk assessment and mitigation strategies into opioid pain management plans in oncology patients

• List pharmacologic and non-pharmacologic strategies to reduce the use of opioids used to treat pain in the oncology patient

1:45 p.m. – 2:30 p.m. LEARNING OBJECTIVES:

New Drug Updates in Oncology Jamie Kalangara Thomas, PharmD • Describe the mechanisms of action for the newly approved

agents: alpelisib, tagraxofusp, polatuzumab, and erdafitinib • Review the current literature for these novel agents (alpelisib,

tagraxofusp, polatuzumab, and erdafitinib) • Identify common adverse events, monitoring parameters and

patient education points for alpelisib, tagraxofusp, polatuzumab, and erdafitinib.

2:30 p.m. Closing Remarks

Sandra Cuellar, PharmD, BCOP